Novo Nordisk has submitted NDAs for what could be the first ever oral...
- James MacKenzie Q&A: How late-stage packaging customisation is shaking up the pharmaceutical supply chain
- Obseva’s nolasiban aims to address unmet need by improving IVF outcomes
- Lee’s Pharm and RegeneRx develop ophthalmic drug in China
- Pharma Technology Focus: the absence of antivenom in pharma
- FDA announces another carcinogenic impurity in ARB blood pressure drugs
NDAs submitted to the FDA for the first oral GLP-1 receptor agonist
Novo Nordisk has submitted NDAs for what could be the first ever oral GLP-1 based treatment for type II diabetes. What could this mean for the GLP-1 market?
Governments are playing a bigger role in cell and gene therapy manufacturing
Currently, the UK accounts for 16% of global cell therapy manufacturing facilities, according to GlobalData’s Contract Service Provider Database.
Innovation in asthma pipeline is focused on targeted biologic therapies
There is a much more diverse range of molecule types present in the asthma pipeline when compared to the current market space.
James MacKenzie Q&A: How late-stage packaging customisation is shaking up the pharmaceutical supply chain
Tablets in blisters may seem like a simple, everyday item, but in reality the manufacturing process is highly sophisticated. The trend toward smaller batch sizes and higher numbers of packaging variants is driving many manufacturers to turn to ‘postponement’ to improve the efficiency of their supply chains.
Northern India manufacturing on growth trajectory, but still lags behind south
Approximately 70% of all Indian pharmaceutical revenues will be from generics and revenue growth for this segment has been particularly rapid in recent years.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.